Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction of outcomes for high-count monoclonal B lymphocytosis
April 25, 202423m 49s
Audio is streamed directly from the publisher (prfx.byspotify.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and immunogenetic signatures can be used in the prediction of outcomes for high-count monoclonal B lymphocytosis.
Featured Articles:
- Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update
- Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
- High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: The HUNT study
Topics
hematologyoncologymedicalmedical researchlymphomaleukemiaCAR Tred cells